Yubo Wang

1.9k total citations
69 papers, 1.4k citations indexed

About

Yubo Wang is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Oncology. According to data from OpenAlex, Yubo Wang has authored 69 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 34 papers in Pulmonary and Respiratory Medicine, 26 papers in Molecular Biology and 16 papers in Oncology. Recurrent topics in Yubo Wang's work include Lung Cancer Treatments and Mutations (27 papers), PI3K/AKT/mTOR signaling in cancer (15 papers) and Metabolism, Diabetes, and Cancer (9 papers). Yubo Wang is often cited by papers focused on Lung Cancer Treatments and Mutations (27 papers), PI3K/AKT/mTOR signaling in cancer (15 papers) and Metabolism, Diabetes, and Cancer (9 papers). Yubo Wang collaborates with scholars based in China, United States and Iran. Yubo Wang's co-authors include Yong He, Li Li, Rui Han, Caiyu Lin, Hengyi Chen, Conghua Lu, Bailong Xiao, Kunlin Li, Fenfen Sun and Hualiang Xiao and has published in prestigious journals such as PLoS ONE, The Journal of Physiology and Clinical Infectious Diseases.

In The Last Decade

Yubo Wang

66 papers receiving 1.4k citations

Peers

Countries citing papers authored by Yubo Wang

Since Specialization

Citations

This map shows the geographic impact of Yubo Wang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yubo Wang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yubo Wang more than expected).

Fields of papers citing papers by Yubo Wang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yubo Wang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yubo Wang. The network helps show where Yubo Wang may publish in the future.

Co-authorship network of co-authors of Yubo Wang

This figure shows the co-authorship network connecting the top 25 collaborators of Yubo Wang. A scholar is included among the top collaborators of Yubo Wang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yubo Wang. Yubo Wang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Effects of 8 days intake of hydrogen-rich water on muscular endurance performance and fatigue recovery during resistance training 2024 ·Frontiers in Physiology ·(unknown), (unknown), (unknown), (unknown), Yubo Wang	1
2	Clinical Management in NSCLC Patients With EGFR Mutation After Osimertinib Progression With Unknown Resistance Mechanisms 2024 ·The Clinical Respiratory Journal ·Xin Liao, Tingting He, (unknown), Pian Liu, Jing Li, Yong He, Yubo Wang	2
3	Tumor immune microenvironment predicts the pathologic response of neoadjuvant chemoimmunotherapy in non–small‐cell lung cancer 2023 ·Cancer Science ·Rui Han, Yimin Zhang, Tianhu Wang, Hualiang Xiao, (unknown), Cheng Shen, (unknown), (unknown), Li Li, Mengxiao Zhu, Haiwei Du, Huan Tang, (unknown), Yubo Wang, Yong He	13
4	Low BMI patients with advanced EGFR mutation-positive NSCLC can get a better outcome from metformin plus EGFR-TKI as first-line therapy: A secondary analysis of a phase 2 randomized clinical trial 2023 ·PubMed ·Rui Han, (unknown), Yubo Wang, (unknown), (unknown), Yong He	2
5	Overall signature of acquired KRAS gene changes in advanced non-small cell lung cancer patient with EGFR-TKI resistance 2023 ·Japanese Journal of Clinical Oncology ·(unknown), (unknown), (unknown), Yubo Wang, Rui Han, Chen Hu, Mengxiao Zhu, Conghua Lu, Caiyu Lin, Di Wu, Yihui Liu, Huan Tang, (unknown), (unknown), Yong He	1
6	The rational application of liquid biopsy based on next‐generation sequencing in advanced non‐small cell lung cancer 2022 ·Cancer Medicine ·(unknown), (unknown), Yongchang Zhang, Rui Han, Yubo Wang, Li Li, Yimin Zhang, Mengxiao Zhu, (unknown), Haiwei Du, Chen Hu, Chengzhi Zhou, Nong Yang, Shangli Cai, Yong He	4
7	Clinical characteristics and risk factors for a prolonged length of stay of patients with asymptomatic and mild COVID-19 during the wave of Omicron from Shanghai, China 2022 ·BMC Infectious Diseases ·Chen Hu, Yukai Liu, (unknown), (unknown), Yuqiang Fang, (unknown), Yubo Wang, Yong He, (unknown), Fan Zeng	2
8	First-Line Osimertinib in Patients With EGFR-Mutated Non-Small Cell Lung Cancer: Effectiveness, Resistance Mechanisms, and Prognosis of Different Subsequent Treatments 2022 ·Clinical Medicine Insights Oncology ·(unknown), (unknown), Jian Zhang, Jie Dai, Zhulin Liu, Zhenyu Ding, Yubo Wang, Mengxiao Zhu, Chen Hu, Rui Han, Huan Tang, (unknown), Yong He	6
9	Ibrutinib reverses IL-6-induced osimertinib resistance through inhibition of Laminin α5/FAK signaling 2022 ·Communications Biology ·Li Li, Zhujun Li, Conghua Lu, Jianghua Li, Kejun Zhang, Caiyu Lin, Xiaolin Tang, Zhulin Liu, Yimin Zhang, Rui Han, Yubo Wang, Mingxia Feng, Yuan Zhuang, Chen Hu, Yong He	26
10	Genotyping of cerebrospinal fluid in lung cancer patients with leptomeningeal metastasis 2022 ·Thoracic Cancer ·(unknown), Haodong Zhou, Kejun Zhang, Lan Liu, (unknown), Renyuan Wang, Xin Li, Mengxiao Zhu, Chen Hu, Yubo Wang, Zhulin Liu, (unknown), Yong He	5
11	VPS34 suppression reverses osimertinib resistance via simultaneously inhibiting glycolysis and autophagy 2021 ·Carcinogenesis ·Hengyi Chen, Conghua Lu, Caiyu Lin, Li Li, Yubo Wang, Rui Han, Chen Hu, Yong He	9
12	Metformin reduces HGF-induced resistance to alectinib via the inhibition of Gab1 2020 ·Cell Death and Disease ·Hengyi Chen, Caiyu Lin, Tao Peng, (unknown), Conghua Lu, Li Li, Yubo Wang, Rui Han, Mingxia Feng, Fenfen Sun, Yong He	20
13	Metformin attenuates TGF-β1-induced pulmonary fibrosis through inhibition of transglutaminase 2 and subsequent TGF-β pathways 2020 ·3 Biotech ·Yubo Wang, Caiyu Lin, Rui Han, Conghua Lu, Li Li, Chen Hu, Mingxia Feng, Hengyi Chen, Yong He	12
14	Aspirin sensitizes osimertinib‐resistant NSCLC cells in vitro and in vivo via Bim‐dependent apoptosis induction 2020 ·Molecular Oncology ·Rui Han, Shuai Hao, Conghua Lu, Chong Zhang, Caiyu Lin, Li Li, Yubo Wang, Chen Hu, Yong He	26
15	Characterization of an Asymptomatic Cohort of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infected Individuals Outside of Wuhan, China 2020 ·Clinical Infectious Diseases ·Yubo Wang, Yong He, Tong Jin, (unknown), Ting Xie, (unknown), Jiànróng Lǐ, (unknown), Yong Cui, Elizabeth S. Higgs, Jianglin Xiang	68
16	Serial ultra‐deep sequencing of circulating tumor DNA reveals the clonal evolution in non‐small cell lung cancer patients treated with anti‐PD1 immunotherapy 2019 ·Cancer Medicine ·Li Li, Yubo Wang, Weiwei Shi, Mengxiao Zhu, Zhulin Liu, (unknown), Yanwu Zeng, Yong He	26
17	Polybrominated diphenyl ethers and incident pregnancy loss: The LIFE Study 2018 ·Environmental Research ·Giehae Choi, Yubo Wang, Rajeshwari Sundaram, Zhen Chen, Dana Boyd Barr, Germaine M. Buck Louis, Melissa M. Smarr	23
18	The Utility of ¹⁸F-FDG PET/CT for Monitoring Response and Predicting Prognosis after Glucocorticoids Therapy for Sarcoidosis 2018 ·BioMed Research International ·Hengyi Chen, Rongbing Jin, Yubo Wang, Li Li, Kunlin Li, Yong He	14
19	Metformin synergistically enhances the antitumor activity of the third‐generation EGFR‐TKI CO‐1686 in lung cancer cells through suppressing NF‐κB signaling 2018 ·The Clinical Respiratory Journal ·(unknown), Caiyu Lin, Conghua Lu, Li Li, Yubo Wang, Hengyi Chen, Yong He	11
20	Metformin Sensitizes EGFR-TKI–Resistant Human Lung Cancer Cells In Vitro and In Vivo through Inhibition of IL-6 Signaling and EMT Reversal 2014 ·Clinical Cancer Research ·Li Li, Rui Han, Hualiang Xiao, Caiyu Lin, Yubo Wang, Hao Liu, Kunlin Li, Hengyi Chen, Fenfen Sun, Zhenzhou Yang, Jianxin Jiang, Yong He	204

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Gary J. Smith Breakdown of academic impact, for papers by Jun Cao Breakdown of academic impact, for papers by Yuri Yamaguchi Breakdown of academic impact, for papers by Russell Petty Breakdown of academic impact, for papers by Huanyu Zhao Breakdown of academic impact, for papers by Kelly M. Quesnelle Breakdown of academic impact, for papers by Hui Tian Breakdown of academic impact, for papers by Qun Zhao